SFRP2

Across TCGA pan-cancer cohorts, SFRP2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SFRP2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SFRP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SFRP2 is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

LUAD, HNSC, and BLCA are the cancer types where SFRP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SFRP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+2.804	<.001	7	view →
HNSC	Female	III,IV	+2.753	.002	7	view →
BLCA	Male	All	−3.460	.003	6	view →
THCA	All	II,III,IV	−2.676	<.001	6	view →
COAD	Female	II,III,IV	−2.001	<.001	6	view →
LUSC	All	II,III,IV	+1.893	<.001	6	view →
BRCA	All	All	+1.023	<.001	6	view →
READ	Female	All	−3.942	.004	2	view →
KIRC	Male	All	+0.889	.040	2	view →
PRAD	All	All	−0.468	.047	2	view →
LIHC	All	All	+0.433	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SFRP2–LUAD

Open the LUAD breakdown →